Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic
  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Oncology Translational Research Leader to Scientific Advisory Board

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has appointed Christoph Reinhard, PhD, MBA, to its Scientific Advisory Board. Reinhard will join other board members who are thought leaders in respective fields to provide invaluable insight into the company’s scientific initiatives and growth strategy. A leader in oncology translational research, new technologies in drug development and external innovation, Reinhard is acting chief scientific officer for CELLphenomics GmbH, where he facilitates and oversees the process of determining what types of novel drugs and drug combinations might best help future cancer patients with solid tumors. Prior to CELLphenomics GmbH, Reinhard worked at Eli Lilly where spearheaded the company’s Innovative Medicine Initiative in Oncology and was directly involved in the development and implementation of the Partners and Outsourcing Strategy for Lilly Singapore’s drug development and biomarker efforts. He is also the cofounder and director of the board of the Asian Cancer Research Group. “We are fortunate to have someone on our Scientific Advisory Board with such extensive experience in the biopharmaceutical industry with a deep understanding of oncology and translational science,” said Predictive Oncology CEO Raymond F. Vennare in the press release. “Dr. Reinhard’s personal and professional commitment is both impressive and honorable, and his insights into oncology drug development will prove invaluable as we continue to gain momentum with oncology drug development partners around the world.”

To view the full press release, visit https://ibn.fm/bhSjF

About Predictive Oncology Inc.

Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the Company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.